tiprankstipranks
Trending News
More News >
CanBas Co., Ltd. (JP:4575)
:4575
Japanese Market
Advertisement

CanBas Co., Ltd. (4575) AI Stock Analysis

Compare
0 Followers

Top Page

JP:4575

CanBas Co., Ltd.

(4575)

Select Model
Select Model
Select Model
Underperform 32 (OpenAI - 4o)
Rating:32Underperform
Price Target:
CanBas Co., Ltd. is facing substantial financial difficulties due to its inability to generate revenue, leading to negative profitability metrics. The technical indicators suggest a bearish trend, and the valuation metrics are unattractive, with a negative P/E ratio and no dividend yield. The strong balance sheet with no debt is a positive, but it does not outweigh the significant operational challenges.

CanBas Co., Ltd. (4575) vs. iShares MSCI Japan ETF (EWJ)

CanBas Co., Ltd. Business Overview & Revenue Model

Company DescriptionCanBas Co., Ltd. (4575) is a biotechnology company based in Japan, primarily focused on the research and development of novel pharmaceuticals. The company is engaged in the discovery and development of small molecule cancer therapeutics, leveraging its proprietary technologies to address unmet medical needs in oncology. CanBas Co., Ltd. aims to advance innovative therapies that can significantly improve patient outcomes, making it a significant player in the pharmaceutical and biotechnology sectors.
How the Company Makes MoneyCanBas Co., Ltd. generates revenue primarily through the successful development and commercialization of its pharmaceutical products and technologies. The company invests in research and development to create proprietary drugs, which it can then license to larger pharmaceutical companies or bring to market itself. Revenue streams include milestone payments from licensing agreements, royalties from drug sales, and potentially direct sales of its pharmaceutical products. Additionally, strategic partnerships and collaborations with other biotech or pharmaceutical firms play a crucial role in its revenue model, providing both financial support and access to broader markets for its developed therapies.

CanBas Co., Ltd. Financial Statement Overview

Summary
CanBas Co., Ltd. faces significant challenges with no revenue or profit generation, heavily relying on equity financing. The absence of revenue growth and negative cash flows from operations are critical concerns, despite a strong balance sheet without debt.
Income Statement
5
Very Negative
CanBas Co., Ltd. shows a significant decline in financial performance with zero revenue over recent periods, leading to negative gross profit and net income. The company's inability to generate revenue is a major concern, with continuous negative EBIT and EBITDA margins indicating operational inefficiencies.
Balance Sheet
40
Negative
The balance sheet reflects a strong equity position and no debt, which is a positive sign of financial stability. However, the lack of revenue generation limits the company's growth potential, and the high equity ratio indicates reliance on shareholder equity without leveraging debt.
Cash Flow
20
Very Negative
Cash flow statements reveal negative operating and free cash flows, highlighting challenges in generating cash from operations. The company's cash position is strong due to financing activities, but sustainable cash generation from operations is missing, posing a long-term risk.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.00108.94M
Gross Profit0.000.00-984.00M-671.00M-608.00M-322.00M
EBITDA-831.00M0.0053.65M-1.28B-848.65M-522.28M
Net Income-1.16B-1.16B-1.21B-1.24B-855.58M-531.03M
Balance Sheet
Total Assets3.05B3.05B2.43B2.09B790.71M1.30B
Cash, Cash Equivalents and Short-Term Investments2.83B2.83B1.89B1.62B737.77M1.15B
Total Debt0.000.000.000.00367.34M749.99M
Total Liabilities107.00M107.00M91.99M153.85M540.02M857.64M
Stockholders Equity2.94B2.94B2.34B1.93B250.69M437.97M
Cash Flow
Free Cash Flow0.00-771.45M-1.28B-1.40B-719.81M-688.57M
Operating Cash Flow0.00-771.45M-1.28B-1.40B-719.81M-688.57M
Investing Cash Flow0.00122.00K0.000.00182.00K0.00
Financing Cash Flow0.001.75B1.54B2.27B282.75M728.80M

CanBas Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price999.00
Price Trends
50DMA
1150.16
Negative
100DMA
1077.34
Negative
200DMA
1027.53
Positive
Market Momentum
MACD
-39.20
Positive
RSI
42.68
Neutral
STOCH
28.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4575, the sentiment is Negative. The current price of 999 is below the 20-day moving average (MA) of 1076.20, below the 50-day MA of 1150.16, and below the 200-day MA of 1027.53, indicating a neutral trend. The MACD of -39.20 indicates Positive momentum. The RSI at 42.68 is Neutral, neither overbought nor oversold. The STOCH value of 28.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4575.

CanBas Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
¥19.94B6.33%-250.29%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
¥24.05B378.77-27.00%
47
Neutral
¥18.33B5.59%
46
Neutral
¥15.18B-22.81%2.69%
41
Neutral
¥56.57B-78.54%10.23%
32
Underperform
¥20.50B9.48%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4575
CanBas Co., Ltd.
1,034.00
52.00
5.30%
JP:4593
Healios KK
476.00
277.00
139.20%
JP:4599
StemRIM Inc.
294.00
-70.00
-19.23%
JP:4889
Renascience Inc.
1,921.00
1,603.00
504.09%
JP:7774
Japan Tissue Engineering Co., Ltd.
495.00
-9.00
-1.79%
JP:7776
CellSeed Inc.
438.00
-117.00
-21.08%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 08, 2025